Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19480811 | 0.86 | CHRNA1 (0.32) | CHRNA1CHRNB4CHRNA3CHRNA7EPHX2 | |
| SCHEMBL21671072 | 0.82 | CHRNA1 (0.31) | CHRNA1CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL9610944 | 0.81 | MEN1 (0.44) | EPHX2 | |
| SCHEMBL3766102 | 0.79 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL8519485 | 0.79 | L3MBTL1 (0.35) | L3MBTL1MAPT | |
| SCHEMBL412139 | 0.79 | NOTUM (0.34) | L3MBTL1 | |
| SCHEMBL411505 | 0.79 | NOTUM (0.43) | L3MBTL1 | |
| SCHEMBL17321298 | 0.77 | MEN1 (0.36) | L3MBTL1EPHX2 | |
| SCHEMBL5789048 | 0.76 | SIRT2 (0.33) | L3MBTL1 | |
| SCHEMBL5789342 | 0.76 | NOTUM (0.35) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025038930-A1 | AZEPANE AND PYRROLIDINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS, INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | AQUINNAH PHARMACEUTICALS INC (US) | 2023-09-28 | — | — | US | disclosed |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | THE SCRIPPS RESEARCH INSTITUTE (US) | 2023-07-25 | — | — | US | disclosed |
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | THE SCRIPPS RESEARCH INSTITUTE | 2023-01-26 | — | — | US | disclosed |
| EP-1225882-B1 | SELECTIVE COX-2 INHIBITORY NOVEL ESTERS FROM INDOLEALKANOLS AND NOVEL AMIDES FROM INDOLEALKYLAMINES | UNIV VANDERBILT (US) | 2007-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024012-A1 | Protease Inhibitors for Treatment of Coronavirus Infections | ACE, ACE2, TMPRSS2 | L3MBTL1 1759/4885CHRNA1 3733/4885CHRNB4 4558/4885 |
| US-20230303489-A1 | COMPOUNDS, COMPOSITIONS AND METHODS OF USE | FUS, TFEB, CLN6 | L3MBTL1 2372/4885CHRNA1 4855/4885CHRNB4 4418/4885 |
| US-11708348-B2 | Protease inhibitors for treatment of coronavirus infections | ACE, ACE2, TMPRSS2 | L3MBTL1 1759/4885CHRNA1 3733/4885CHRNB4 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.